Survey of Ophthalmology
Volume 47, Issue 3 , Pages 239-256 , May 2002

Matrix Metalloproteinases in Disease and Repair Processes in the Anterior Segment

  • Tina T.L Wong, MRCOphth

      Affiliations

    • Wound Healing Research Unit, Departments of Pathology and Glaucoma, Institute of Ophthalmology and Moorfields Eye Hospital, London,UK
    • Corresponding Author InformationReprint address: Tina T. L. Wong BSc, MRCOphth, Wound Healing Research Unit, Departments of Pathology and Glaucoma, Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.
    • ,
  • Charanjit Sethi, FRCOphth

      Affiliations

    • Wound Healing Research Unit, Departments of Pathology and Glaucoma, Institute of Ophthalmology and Moorfields Eye Hospital, London,UK
    • ,
  • Julie T Daniels, PhD

      Affiliations

    • Wound Healing Research Unit, Departments of Pathology and Glaucoma, Institute of Ophthalmology and Moorfields Eye Hospital, London,UK
    • ,
  • G.Astrid Limb, PhD

      Affiliations

    • Wound Healing Research Unit, Departments of Pathology and Glaucoma, Institute of Ophthalmology and Moorfields Eye Hospital, London,UK
    • ,
  • Gillian Murphy, PhD

      Affiliations

    • School of Biological Sciences, University of East Anglia, Norwich, UK
    • ,
  • Peng T Khaw, FRCOphth

      Affiliations

    • Wound Healing Research Unit, Departments of Pathology and Glaucoma, Institute of Ophthalmology and Moorfields Eye Hospital, London,UK

References 

  1. Acott TS, Kingsley PD, Samples JR, Van Buskirk EM. Human trabecular meshwork organ culture (morphology and glycosaminoglycan synthesis). Invest Ophthalmol Vis Sci. 1988;29:90–100
  2. Acott TS, Westcott M, Passo MS, Van Buskirk EM. Trabecular meshwork glycosaminoglycans in human and cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 1985;26:1320–1329
  3. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795–798
  4. Afonso AA, Sobrin L, Monroy DC, et al.  Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506–2512
  5. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172–180
  6. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumour cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst. 1990;82:589–595
  7. Amour A, Slocombe PM, Webster A, et al.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39–44
  8. Ando H, Twining SS, Yue BY, et al.  MMPs and proteinase inhibitors in the human aqueous humor. Invest Ophthalmol Vis Sci. 1993;34:3541–3548
  9. Anthony TL, Pierce KL, Stamer WD, Regan JW. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315–321
  10. Apte SS, Fukai N, Beier DR, Olsen BR. The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. J Biol Chem. 1997;272:25511–25517
  11. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem. 1995;270:14313–14318
  12. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977;14:53–65
  13. Azar DT, Hahn TW, Jain S, et al.  Matrix metalloproteinases are expressed during wound healing after excimer laser keratectomy. Cornea. 1996;15:18–24
  14. Baramova E, Foidart JM. Matrix metalloproteinase family. Cell Biol Int. 1995;19:239–242
  15. Barletta JP, Angella G, Balch KC, et al.  Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Invest Ophthalmol Vis Sci. 1996;37:20–28
  16. Barro CD, Romanet JP, Fdili A, et al.  Gelatinase concentration in tears of corneal-grafted patients. Curr Eye Res. 1998;17:174–182
  17. Bernatchez SF, Tabatabay C, Belin D. Urokinase-type plasminogen activator in human aqueous humor. Invest Ophthalmol Vis Sci. 1992;33:2687–2692
  18. Bernstein EF, Chen YQ, Kopp JB, et al.  Long-term sun exposure alters the collagen of the papillary dermis. Comparison of sun-protected and photoaged skin by northern analysis, immunohistochemical staining, and confocal laser scanning microscopy. J Am Acad Dermatol. 1996;34:209–218
  19. Bernstein EF, Chen YQ, Tamai K, et al.  Enhanced elastin and fibrillin gene expression in chronically photodamaged skin. J Invest Dermatol. 1994;103:182–186
  20. Bernstein EF, Fisher LW, Li K, et al.  Differential expression of the versican and decorin genes in photoaged and sun-protected skin. Comparison by immunohistochemical and northern analyses. Lab Invest. 1995;72:662–669
  21. Bill A. Uveoscleral drainage of aqueous humor (physiology and pharmacology). Prog Clin Biol Res. 1989;312:417–427
  22. Bill A. The drainage of aqueous humour. Invest Ophthalmol Vis Sci. 1975;14:1–13
  23. Birkedal Hansen H. From tadpole collagenase to a family of matrix metalloproteinases. J Oral Pathol. 1988;17:445–451
  24. Bode W, Fernandez-Catalan C, Grams F, et al.  Insights into MMP-TIMP interactions. Ann NY Acad Sci. 1999;878:73–91
  25. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines (an absolute requirement for transcription factor NF-kappa B). FEBS Lett. 1998;435:29–34
  26. Boujrad N, Ogwuegbu SO, Garnier M, et al.  Identification of a stimulator of steroid hormone synthesis isolated from testis. Science. 1995;268:1609–1612
  27. Bradley JM, Vranka J, Colvis CM, et al.  Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649–2658
  28. Brenner DA, OHara M, Angel P, et al.  Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature. 1989;337:661–663
  29. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases (evolution, structure and function). Biochim Biophys Acta. 2000;1477:267–283
  30. Brown D, Chwa MM, Opbroek A, Kenney MC. Keratoconus corneas (increased gelatinolytic activity appears after modification of inhibitors). Curr Eye Res. 1993;12:571–581
  31. Bullen EC, Longaker MT, Updike DL, et al.  Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol. 1995;104:236–240
  32. Buller C, Johnson DH, Tschumper RC. Human trabecular meshwork phagocytosis. Observations in an organ culture system. Invest Ophthalmol Vis Sci. 1990;31:2156–2163
  33. Bumett JM, Smith LE, Prause JW. Acute inflammatory cells and collagenase in tears of human melting corneas. Invest Ophthalmol Vis Sci. 1981;20:S173;[abstract]
  34. Butler GS, Will H, Atkinson SJ, Murphy G. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997;244:653–657
  35. Buttice G, Quinones S, Kurkinen M. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene. Nucleic Acids Res. 1991;19:3723–3731
  36. Cawston T. Matrix metalloproteinases and TIMPs (properties and implications for the rheumatic diseases). Mol Med Today. 1998;4:130–137
  37. Cawston T. Matrix metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther. 1996;70:163–182
  38. Chandler S, Miller KM, Clements JM, et al.  Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis (an overview). J Neuroimmunol. 1997;72:155–161
  39. Chang JH, Kook MC, Lee JH, et al.  Effects of synthetic inhibitor of metalloproteinase and cyclosporin A on corneal haze after excimer laser photorefractive keratectomy in rabbits. Exp Eye Res. 1998;66:389–396
  40. Clark RA, Ashcroft GS, Spencer MJ, et al.  Re-epithelialization of normal human excisional wounds is associated with a switch from alpha v beta 5 to alpha v beta 6 integrins. Br J Dermatol. 1996;135:46–51
  41. Collier IE, Wilhelm SM, Eisen AZ, et al.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem. 1988;263:6579–6587
  42. Cornelius LA, Nehring LC, Roby JD, et al.  Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol. 1995;105:170–176
  43. Coroneo MT. Pterygium as an early indicator of ultraviolet insolation (a hypothesis). Br J Ophthalmol. 1993;77:734–739
  44. Crawford HC, Matrisian LM. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein. 1996;49:20–37
  45. Curran T, Franza BR. Fos and Jun (the AP-1 connection). Cell. 1988;55:395–397
  46. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 1990;63:21–29
  47. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999;117:498–503
  48. DeClerck YA, Perez N, Shimada H. Inhibition of invasion and metastasis in cell transfected with an inhibitor of metalloproteinases. Cancer Res. 1992;52:701–708
  49. Desjardins DC, Parrish RK, Folberg R, et al.  Wound healing after filtering surgery in owl monkeys. Arch Ophthalmol. 1986;104:1835–1839
  50. Di Girolamo N, McCluskey P, Lloyd A, et al.  Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:671–679
  51. Di Girolamo N, Verma MJ, McCluskey PJ, et al.  Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15:1060–1068
  52. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863–868
  53. Edwards DR, Rocheleau H, Sharma RR, et al.  Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta. 1992;1171:41–55
  54. Ehrlich HP, Keefer KA, Myers RL, Passaniti A. Vanadate and the absence of myofibroblasts in wound contraction. Arch Surg. 1999;134:494–501
  55. Fini ME, Cook JR, Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res. 1998;290(Suppl):S12–S23
  56. Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990;31:1779–1788
  57. Fini ME, Parks WC, Rinehart WB. Role of matrix metalloproteinses in failure to re-epithelialize after corneal injury. Am J Pathol. 1996;149:1287–1302
  58. Fini ME, Yue BY, Sugar J. Collagenolytic/gelatinolytic metalloproteinases in normal and keratoconus corneas. Curr Eye Res. 1992;11:849–862
  59. Fisher GJ, Datta SC, Talwar HS, et al.  Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379:335–339
  60. Fukuda Y, Ishizaki M, Kudoh S, et al.  Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest. 1998;78:687–698
  61. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27:549–550
  62. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389–402
  63. Gailit J, Clark RA. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol. 1994;6:717–725
  64. Garrana RM, Petroll WM, Chen WT. Radial keratotomy. II. Role of the myofibroblast in corneal wound contraction. Invest Ophthalmol Vis Sci. 1992;33:3271–3282
  65. Garrana RMR, Zieske JD, Assouline M. Matrix metalloproteinases in epithelia from human recurrent corneal erosion. Invest Ophthalmol Vis Sci. 1999;40:1266–1270
  66. Gaton DD, Sagara T, Lindsey JD, Weinreb RN. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest Ophthalmol Vis Sci. 1999;40:363–369
  67. Geerling G, Joussen AM, Daniels JT, et al.  Matrix metalloproteinases in sterile corneal melts. Ann NY Acad Sci. 1999;878:571–574
  68. Giannelli G, Falk-Marzillier J, Schiraldi O, et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277:225–228
  69. Girard MT, Matsubara M, Fini ME. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells. Invest Ophthalmol Vis Sci. 1991;32:2441–2454
  70. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996;156:1–4
  71. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases (structure, regulation and biological functions). Eur J Cell Biol. 1997;74:111–122
  72. Greene J, Wang M, Liu YE, et al.  Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996;271:30375–30380
  73. Grierson I, Day J, Unger WG, Ahmed A. Phagocytosis of latex microspheres by bovine meshwork cells in culture. Graefes Arch Clin Exp Ophthalmol. 1986;224:536–544
  74. Gross J, Nagai Y. Specific degradation of the collagen molecule by tadpole collagenolytic enzyme. Biochemistry. 1965;54:1197–1204
  75. Guedez L, Stetler Stevenson WG, Wolff L, et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998;102:2002–2010
  76. Hanyu T. The effects of single mitomycin C application on the expression of matrix metalloproteinases in the sclera and aqueous of albino rabbits. Nippon Gan Gakkai Zasshi (Japan). 1999;103:186–192
  77. Hassell JR, Cintron C, Kublin C, Newsome DA. Proteoglycan changes during restoration of transparency in corneal scars. Arch Biochem Biophys. 1983;222:362–369
  78. Hayakawa T, Yamashita K, Ohuchi E. Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). J Cell Sci. 1994;107:2373–2379
  79. Hayakawa T, Yamashita K, Tanzawa K. Growth promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. FEBS Lett. 1992;298:29–32
  80. Hernandez Barrantes S, Toth M, Bernardo MM. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem. 2000;275:12080–12089
  81. Hiraoka N, Allen E, Apel IJ, et al.  Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95:365–377
  82. Hitchings R, Grierson I. Clinicopathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc. 1983;103:84–88
  83. Hoshino M, Nakamura Y, Sim J, et al.  Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol. 1998;102:783–788
  84. Huang SH, Adamis AP, Wiederschain DG, et al.  Matrix metalloproteinases and their inhibitors in aqueous humor. Exp Eye Res. 1996;62:481–490
  85. Ishiguro N, Ito T, Miyazaki K, Iwata H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J Rheumatol. 1999;26:34–40
  86. Itoh Y, Nagase H. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem. 1995;270:16518–16521
  87. Jampel HD, McGuigan LJ, Dunkelberger GR, et al.  Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol. 1988;106:89–94
  88. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110:1049–1050[letter]
  89. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9:963–969
  90. Jeffrey JJ. Collagen and collagenase (pregnancy and parturition). Semin Perinatol. 1991;15:118–126
  91. Jester JV, Petroll WM, Barry PA, Cavanagh HD. Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing. Invest Ophthalmol Vis Sci. 1995;36:809–819
  92. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;2:466–471
  93. Johnson MD, Kim HR, Chesler L, et al.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol. 1994;160:194–202
  94. Kahari VM, Saarialho Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31:34–45
  95. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen (degradation by migrating endothelial cells). Science. 1983;221:281–283
  96. Karai I, Horiguchi S. Pterygium in welders. Br J Ophthalmol. 1984;68:347–349
  97. Katz G, Higginbotham E, Litcher P. Mitomycin-C versus 5-fluorouracil in high-risk glaucoma filtration surgery (extended follow-up). Ophthalmology. 1995;102:1263–1269
  98. Kawashima Y, Saika S, Yamanaka O. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues. Curr Eye Res. 1998;17:445–451
  99. Kenney MC, Chwa M, Alba A, et al.  Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas. Curr Eye Res. 1998;17:238–246
  100. Kenney MC, Chwa M, Escobar M, Brown D. Altered gelatinolytic activity by keratoconus corneal cells. Biochem Biophys Res Commun. 1989;161:353–357
  101. Kernacki KA, Fridman R, Hazlett LD, et al.  In vivo characterization of host and bacterial protease expression during Pseudomonas aeruginosa corneal infections in naive and immunized mice. Curr Eye Res. 1997;16:289–297
  102. Kernacki KA, Hobden JA, Hazlett LD, et al.  In vivo bacterial protease production during Pseudomonas aeruginosa corneal infection. Invest Ophthalmol Vis Sci. 1995;36:1371–1378
  103. Kerr LD, Holt JT, Matrisian LM. Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways. Science. 1988;242:1424–1427
  104. Kjeldsen L, Sengelov H, Lollike K, et al.  Isolation and characterization of gelatinase granules from human neutrophils. Blood. 1994;83:1640–1649
  105. Kleiner DE, Stetler Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol. 1993;5:891–897
  106. Knepper PA, Farbman AI, Telser AG. Aqueous outflow pathway glycosaminoglycans. Exp Eye Res. 1981;32:265–277
  107. Koivukangas V, Kallioinen M, Autio-Harmainen H, Oikarinen A. UV irradiation induces the expression of gelatinases in human skin in vivo. Acta Derm Venereol. 1994;74:279–282
  108. Kolb C, Mauch S, Krawinkel U, Sedlacek R. Matrix metalloproteinase-19 in capillary endothelial cells (expression in acutely, but not in chronically, inflamed synovium). Exp Cell Res. 1999;250:122–130
  109. Kolb C, Mauch S, Peter HH, et al.  The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol Lett. 1997;57:83–88
  110. Kon CH, Occleston NL, Charteris D, et al.  A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:1524–1529
  111. Konttinen YT, Halinen S, Hanemaaijer R, et al.  Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogrens syndrome. Matrix Biol. 1998;17:335–347
  112. Kossakowska AE, Edwards DR, Lee SS, et al.  Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol. 1998;153:1895–1902
  113. Kossakowska AE, Urbanski SJ, Watson A. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood. 1991;77:12475–12481
  114. Kratz Owens KL, Hageman GS, Schanzlin DJ. An in-vivo technique for monitoring keratocyte migration following lamellar keratoplasty. Refract Corneal Surg. 1992;8:230–234
  115. Kvanta A, Sarman S, Fagerholm P. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp. Eye Res. 2000;70:419–428
  116. Lamping K, Belkin J. 5-Fluorouracil and mitomycin-C in pseudophakic patients. Ophthalmology. 1995;102:70–75
  117. Langer R, Conn H, Vacanti J, et al.  Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci USA. 1980;77:4331–4335
  118. Lanigan L, Sturmer J, Baez KA: Single intraoperative applications of 5-fluorouracil during filtration surgery: early results. Br J Ophthalmol 78:33–7,
  119. Laurie GW, Leblond CP, Martin GR. Localization of type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of basement membranes. J Cell Biol. 1982;95:340–344
  120. Li DQ, Lee SB, Gunja-Smith Z, et al.  Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts. Arch Ophthalmol. 2001;119:71–80
  121. Li DQ, Meller D, Liu Y, Tseng SC. Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts. Invest Ophthalmol Vis Sci. 2000;41:404–410
  122. Lindsey JD, Kashiwagi K, Boyle D, et al.  Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869–875
  123. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism (implications for uveoscleral outflow). Surv Ophthalmol. 1997;41(Suppl 2):S53–S59
  124. Liu D. Conjunctivochalasis (a cause of tearing and its management). Ophthal Plast Reconstr Surg. 1986;2:25–28
  125. Madlener M, Parks WC, Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res. 1998;242:201–210
  126. Maeda M, Vanlandingham BD, Ye H, et al.  Immunoconfocal localization of gelatinase B expressed by migrating intrastromal epithelial cells after deep annular excimer keratectomy. Curr Eye Res. 1998;17:836–843
  127. Marcantonio JM, Rakic JM, Vrensen GF, Duncan G. Lens cell populations studied in human donor capsular bags with implanted intraocular lenses. Invest Ophthalmol Vis Sci. 2000;41:1130–1141
  128. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases (structures, evolution, and diversification). FASEB J. 1998;12:1075–1095
  129. Matsubara M, Girard MT, Kublin CL, et al.  Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea. Dev Biol. 1991;147:425–439
  130. Matsuo T, Cynader MS. Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye. Br J Ophthalmol. 1992;76:210–213
  131. Mattila L, Airola K, Ahonen M, et al.  Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol. 1998;110:416–421
  132. Menashi S, Vlodavsky I, Ishai-Michaeli R, et al.  The extracellular matrix produced by bovine corneal endothelial cells contains progelatinase A. FEBS Lett. 1995;361:61–64
  133. Messent AJ, Tuckwell DS, Knauper V, et al.  Effects of collagenase-cleavage of type I collagen on alpha2beta1 integrin-mediated cell adhesion. J Cell Sci. 1998;111:1127–1135
  134. Miralles F, Battelino T, Czernichow P, Scharfmann R. TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2. J Cell Biol. 1998;143:827–836
  135. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation (a positive correlation). Br J Ophthalmol. 1984;68:343–346
  136. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15:180–189
  137. Moses MA, Marikovsky M, Harper JW, et al.  Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996;60:379–386
  138. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 1995;248:496–510
  139. Murphy G, Willenbrock F, Crabbe T, et al.  Regulation of matrix metalloproteinase activity. Ann NY Acad Sci. 1994;732:31–41
  140. Nagase H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res. 1998;8:179–186
  141. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 1993;100:1305–1311
  142. Nishida T, Tanaka T. Extracellular matrix and growth factors in corneal wound healing. Curr Opin in Ophthalmol. 1996;7:2–11
  143. Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res. 1999;81:189–195
  144. Nwomeh BC, Liang HX, Diegelmann RF, et al.  Dynamics of the matrix metalloproteinases MMP-1 and MMP-8 in acute open human dermal wounds. Wound Repair Regen. 1998;6:127–134
  145. Occleston NL, Khaw PT. Wound Healing (laboratory investigation and modulating agents). In:  Halliday A,  Hume BJ,  Poston L, et al. editor. An Introduction to Vascular Biology. Cambridge: Cambridge University Press; 1998;p. 197–224
  146. Occleston NL, Tarnuzzer RW, Waters L. Inhibition of matrix metalloproteinases inhibits anterior segment fibroblast mediated collagen contraction. Invest Ophthalmol Vis Sci. 1996;37(Suppl):S1015;[abstract]
  147. Ocklind A, Lake S, Wentzel P. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomologus monkey eye. Invest Ophthalmol Vis Sci. 1996;37:716–726
  148. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267:3581–3584
  149. Okada Y, Harris ED, Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J. 1988;254:731–741
  150. Ozerdem U, Mach-Hofacre B, Cheng L, et al.  The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res. 2000;20:447–453
  151. Parrish R, Minckler D. Late endophthalmitis—filtering surgery time bomb?. Ophthalmology. 1996;103:1167–1168
  152. Parshley DE, Bradley JM, Fisk A, et al.  Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest Ophthalmol Vis Sci. 1996;37:795–804
  153. Parshley DE, Bradley JM, Samples JR, et al.  Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res. 1995;14:537–544
  154. Paterson CA, Wells JG, Koklitis PA, et al.  Recombinant tissue inhibitor of metalloproteinases type 1 suppresses alkali-burn-induced corneal ulceration in rabbits. Invest Ophthalmol Vis Sci. 1994;35:677–684
  155. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995;375:244–247
  156. Pendas AM, Knauper V, Puente XS, et al.  Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem. 1997;272:4281–4286
  157. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol. 1992;99:440–444
  158. Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogrens syndrome. Arch Ophthalmol. 1980;98:89–94
  159. Pilcher BK, Wang M, Qin XJ, et al.  Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann NY Acad Sci. 1999;878:12–24
  160. Pinkerton OD. Bulbar conjunctivo-chalasis. Arch Ophthalmol. 1972;88:532
  161. Reich R, Daphna-Iken D, Chun SY, et al.  Preovulatory changes in ovarian expression of collagenases and tissue metalloproteinase inhibitor messenger ribonucleic acid (role of eicosanoids). Endocrinology. 1991;129:1869–1875
  162. Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases (a functional balance in tissue degradation). Oral Dis. 1996;2:70–76
  163. Rohen JW, van der Zypen E. The phagocytic activity of the trabecularmeshwork endothelium. An electron-microscopic study of the vervet (Cercopithecus aethiops). Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1968;175:143–160
  164. Saarialho-Kere U, Kerkela E, Jeskanen L, et al.  Accumulation of matrilysin (MMP-7) and macrophage metalloelastase (MMP- 12) in actinic damage. J Invest Dermatol. 1999;113:664–672
  165. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, et al.  Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest. 1994;94:79–88
  166. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993;34:3386–3395
  167. Sang QA, Bodden MK, Windsor LJ. Activation of human progelatinase A by collagenase and matrilysin (activation of procollagenase by matrilysin). J Protein Chem. 1996;15:243–253
  168. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998;8:171–177
  169. Santavicca M, Noel A, Angliker H, et al.  Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J. 1996;315:953–958
  170. Sato H, Kinoshita T, Takino T, et al.  Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett. 1996;393:101–104
  171. Sato T, Foged NT, Delaisse JM. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res. 1998;13:59–66
  172. Saw SM, Tan D. Pterygium (prevalence, demography and risk factors). Ophthalmic Epidemiol. 1999;6:219–228
  173. Saxby L, Rosen E, Boulton M. Lens epithelial cell proliferation, migration, and metaplasia following capsulorhexis. Br J Ophthalmol. 1998;82:945–952
  174. Schachtschabel DO, Rohen JW, Wever J, Sames K. Synthesis and composition of glycosaminoglycans by cultured human trabecular meshwork cells. Graefes Arch Clin Exp Ophthalmol. 1982;218:113–117
  175. Scharffetter K, Wlaschek M, Hogg A, et al.  UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res. 1991;283:506–511
  176. Schonthal A, Herrlich P, Rahmsdorf HJ, Ponta H. Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell. 1988;54:325–334
  177. Schultz GS, Strelow S, Stern GA, et al.  Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases. Invest Ophthalmol Vis Sci. 1992;33:3325–3331
  178. Scott KA, Wood EJ, Karran EH. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett. 1998;441:137–140
  179. Sedlacek R, Mauch S, Kolb B, et al.  Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology. 1998;198:408–423
  180. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 1999;107:137–143
  181. Seiler T, Holschbach A, Derse M, et al.  Complications of myopic photorefractive keratectomy with the excimer laser. Ophthalmology. 1994;101:153–160
  182. Seiler T, Wollensak J. Myopic photorefractive keratectomy with the excimer laser. One-year follow-up. Ophthalmology. 1991;98:1156–1163
  183. Sethi CS, Bailey TA, Luthert PJ, Chong NH. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol. 2000;84:654–666
  184. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix (biological consequences). Curr Opin Cell Biol. 1998;10:602–608
  185. Shirato S, Murphy CG, Bloom E, et al.  Kinetics of phagocytosis in trabecular meshwork cells. Flow cytometry and morphometry. Invest Ophthalmol Vis Sci. 1989;30:2499–2511
  186. Shuman MA, Polansky JR, Merkel C, Alvarado JA. Tissue plasminogen activator in cultured human trabecular meshwork cells. Predominance of enzyme over plasminogen activator inhibitor. Invest Ophthalmol Vis Sci. 1988;29:401–405
  187. Skuta GL, Parrish RK. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149–170
  188. Slansky HH, Gnadinger MC, Itoi M, Dohlman CH. Co-agenase in corneal ulcerations. Arch Ophthalmol. 1969;82:108–111
  189. Smine A, Plantner JJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res. 1997;16:925–929
  190. Smith VA, Hoh HB, Littleton M, Easty DL. Over-expression of a gelatinase A activity in keratoconus. Eye. 1995;9:429–433
  191. Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol. 2001;85:147–153
  192. Sobrin L, Liu Z, Monroy DC, et al.  Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41:1703–1709
  193. Solomon A, Li DQ, Lee SB, Tseng SC. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci. 2000;41:2154–2163
  194. Sommer A. Doyne Lecture. Glaucoma (facts and fancies). Eye. 1996;10:295–301
  195. Sorsa T, Mantyla P, Ronka H, et al.  Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann NY Acad Sci. 1999;878:130–140
  196. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol. 1992;114:544–553
  197. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989;264:17374–17378
  198. Stjernschantz J. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:63–68
  199. Stracke JO, Hutton M, Stewart M, et al.  Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem. 2000;275:14809–14816
  200. Strongin AY, Collier I, Bannikov G, et al.  Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331–5338
  201. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT- MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem. 1995;270:23013–23020
  202. Tamiya S, Wormstone IM, Marcantonio JM, et al.  Induction of matrix metalloproteinases 2 and 9 following stress to the lens. Exp Eye Res. 2000;71:591–597
  203. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ. 1995;73:115–121
  204. Toris CB, Yablonski ME, Wang YL, Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995;61:649–657
  205. Toris CB, Yablonski ME, Wang YL, Camras CB. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 1999;127:407–412
  206. Tremble P, Damsky CH, Werb Z. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Cell Biol. 1995;129:1707–1720
  207. Tripathi RC, Park JK, Tripathi BJ, Millard CB. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance. Am J Ophthalmol. 1988;106:719–722
  208. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987;907:191–217
  209. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. Hum Pathol. 1999;30:795–802
  210. Vaalamo M, Weckroth M, Puolakkainen P, et al.  Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol. 1996;135:52–59
  211. Vadillo-Ortega F, Gonzalez-Avila G, Chevez P, et al.  A latent collagenase in human aqueous humor. Invest Ophthalmol Vis Sci. 1989;30:332–335
  212. Valente P, Fassina G, Melchiori A, et al.  TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998;75:246–253
  213. Wagoner MD. Chemical injuries of the eye (current concepts in pathophysiology and therapy). Surv Ophthalmol. 1997;41:275–313
  214. Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992;4:1–5
  215. Wakefield D, McCluskey P, Roche N. Aqueous humour cytokine profile in patients with chronic uveitis. Ocular Immunol Inflamm. 1995;3:203–208
  216. Weinreb RN, Kashiwagi K, Kashiwagi F, et al.  Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772–2780
  217. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13:781–792
  218. White LA, Brinckerhoff CE. Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. Matrix Biol. 1995;14:715–725
  219. Will H, Atkinson SJ, Butler GS, et al.  The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-. 1996;2(and TIMP-3. J Biol Chem 271):17119–17123
  220. Wlaschek M, Heinen G, Poswig A, et al.  UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP- 1 by interrelated loops of interleukin-1 and interleukin-6. Photochem Photobiol. 1994;59:550–556
  221. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145–2154
  222. Woessner JF. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann NY Acad Sci. 1999;878:388–403
  223. Wong WW. A hypothesis on the pathogenesis of pterygiums. Ann Ophthalmol. 1978;10:303–308
  224. Wormstone IM, Liu CS, Rakic JM, et al.  Human lens epithelial cell proliferation in a protein-free medium. Invest Ophthalmol Vis Sci. 1997;38:396–404
  225. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993;101:64–68
  226. Yamachika S, Nanni JM, Nguyen KH, et al.  Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjogrens syndrome. J Rheumatol. 1998;25:2371–2380
  227. Ye HQ, Maeda M, Yu FS, Azar DT. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP- 13) genes in normal and wounded rat corneas. Invest Ophthalmol Vis Sci. 2000;41:2894–2899
  228. Yue BY, Elner VM, Elner SG, Davis HR. Lysosomal enzyme activities in cultured trabecular-meshwork cells. Exp Eye Res. 1987;44:891–897
  229. Zhou L, Sawaguchi S, Twining SS, et al.  Expression of degradative enzymes and protease inhibitors in corneas with keratoconus. Invest Ophthalmol Vis Sci. 1998;39:1117–1124

PII: S0039-6257(02)00287-4

Survey of Ophthalmology
Volume 47, Issue 3 , Pages 239-256 , May 2002

Article Tools

* Image Usage & Resolution